Navigation Links
FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
Date:10/19/2010

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Atrial fibrillation, which affects more than 2 million Americans, involves very fast and uncoordinated contractions of the heart's two upper heart chambers (atria) and is one of the most common types of abnormal heart rhythm.

"People with atrial fibrillation are at a higher risk of developing blood clots, which can cause a disabling stroke if the clots travel to the brain," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA's Center for Drug Evaluation and Research.

Pradaxa is an anticoagulant that acts by inhibiting thrombin, an enzyme in the blood that is involved in blood clotting. The safety and efficacy of Pradaxa were studied in a clinical trial comparing Pradaxa with the anticoagulant warfarin. In the trial, patients taking Pradaxa had fewer strokes than those who took warfarin.

"Unlike warfarin, which requires patients to undergo periodic monitoring with blood tests, such monitoring is not necessary for Pradaxa," Stockbridge says.

As with other approved anti-clotting drugs, bleeding, including life-threatening and fatal bleeding, was among the most common adverse reactions reported by patients treated with Pradaxa. Gastrointestinal symptoms, including an uncomfortable feeling in the stomach (dyspepsia), stomach pain, nausea, heartburn, and bloating also were reported.

Pradaxa was approved with a Medication Guide that informs patients of the
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Botox to Treat Chronic Migraine
2. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
3. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
4. FDA Approves Combination Contraceptive Containing a Folate
5. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
6. FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters
7. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
8. FDA Approves Pediatric Use of Chemical Poisoning Treatment
9. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
10. FDA Approves Vaccines for the 2010-2011 Influenza Season
11. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 A German Diabetes ... L. reuteri probiotic enriches human gut microbiota ... insulin secretion.  The study involved daily administration of Nutraceutix,s ... tablets using the patented BIO- tract ® ... stomach acid on their way to the intestinal tract. ...
(Date:7/28/2015)... , July 28, 2015  SeraCare Life Sciences, ... manufacturers, announced today at the American Association of ... a licensing agreement with the University of California, ... 21 (T21), Trisomy 18 (T18) and Trisomy 13 ... for creating "patient-like" reference materials for Non-Invasive Prenatal ...
(Date:7/28/2015)... -- The Physician-Patient Alliance for Health & Safety (PPAHS) ... Your Hospital Stay ." "Help us ensure ... these patients went home from hospital," said Michael ... to the patient stories presented at the ... Continuous Monitoring of Patients on Opioids (shown above). ...
Breaking Medicine Technology:Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 3Surviving Your Hospital Stay: Physician-Patient Alliance for Health & Safety Launches Fundraising for Patient Safety 2
... Verathon Inc. is pleased to announce that ... manufacturing facility has made enhancements to GlideScope GVL®, ... to better withstand more rigorous vaporized hydrogen peroxide ... disinfection and sterilization systems in the market prompted ...
... /PRNewswire-Asia/ -- Tongjitang Chinese Medicines Company ("Tongjitang" or the ... has called an extraordinary general meeting of shareholders (the ... on Thursday, March 31, 2011, at the Company,s offices ... 1019 Nanhai Avenue, Nanshan District, Shenzhen, 518067 Guangdong Province, ...
Cached Medicine Technology:Verathon Enhances GlideScope® Video Laryngoscopes to Accommodate Newer Vaporized Hydrogen Peroxide Disinfection and Sterilization Systems 2Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders 2Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders 3
(Date:7/29/2015)... ... July 29, 2015 , ... ... Hackett Hemwall Foundation in March, Steven W. Meier M.D., a prominent orthopedic surgeon ... to qualifying patients with demonstrated financial need. , “We are thrilled for this ...
(Date:7/29/2015)... ... July 29, 2015 , ... Stealth Therapeutics Inc. announced ... Study for the Invisiport at Wheaton Franciscan Healthcare in Milwaukee, Wis. The Invisiport ... less invasive, patient-friendly alternative to traditional chest ports and peripherally inserted central catheters ...
(Date:7/29/2015)... MO (PRWEB) , ... July 29, 2015 , ... ... of a decision from the Judicial Panel on Multidistrict Litigation (JPML), according to ... birth defects research at their website, the Zofran Birth Defects Lawsuit Center. , ...
(Date:7/29/2015)... ... ... The Woodlands and Spring Fit Body Boot Camps have implemented an engaging an ... The new system will track each time a client uses social media to Check ... boot camps will donate 20 cents to a selected charity. , Fit Body Boot ...
(Date:7/29/2015)... ... ... Indiana is known for basketball, the boyhood home of Abraham Lincoln, and ... to expand across the state. , Ray Kennedy, owner of the Zerorez Indianapolis Region, ... we should double our first year’s revenue. More importantly, we are growing repeat ...
Breaking Medicine News(10 mins):Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 3
... LCA-Vision Inc. (Nasdaq: LCAV ), ... Lasik Plus (R) brand, today announced that members of its ... Annual Institutional Investors Conference on Monday, March 9, 2009 at ... at The JW Marriott Grande Lakes Hotel in Orlando, Fla. ...
... /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), ... that the Company has amended the maturity date ... Valens U.S. (formerly Laurus Master Funds). , On ... a near-term extension of this facility, originally scheduled ...
... restructure debt -MCLEAN, Va., March 2 Sunrise Senior Living, ... and operating data for the fourth quarter and the full-year ... Monday, March 2, 2009, at 9:00 a.m. ET, to discuss ... life for seniors has been Sunrise,s mission since 1981, and ...
... Cardiac Science Corporation (Nasdaq: CSCX ), ... and informatics products, announced today that it will release ... 12, 2009 after the market close. The Company has ... 4:30 p.m. Eastern Time. During the call, Cardiac ...
... March 2 Alexza Pharmaceuticals, Inc. (Nasdaq: ... Noymer, PhD has been promoted to Vice President, ... position, he will have oversight responsibilities for device ... technology programs.Dr. Noymer joined Alexza in 2006 and ...
... APA,s Psychologically Healthy Workplace Awards, Ten Honored for ... of the economy can be felt across all ... during tough economic times reap rewards for employer ... (APA) at its Psychologically Healthy Workplace Awards ceremony ...
Cached Medicine News:Health News:Bioniche Revolving Credit Facility Maturity Date Amended 2Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 2Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 3Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 4Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 5Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 6Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 7Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 8Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 9Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 10Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 11Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 12Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 13Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 14Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 15Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 16Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 17Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 18Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 19Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 20Health News:Cardiac Science Schedules Fourth Quarter Earnings Release and Announces Conference Call 2Health News:Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D 2Health News:Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D 3Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 2Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 3Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 4
... ACULAR® ophthalmic solution is a prescription ... instruct you to use after your ... eyes and may cause them to ... symptoms of inflammation include redness and ...
Basic-level interpretive resting ECG...
Mid-level interpretive resting ECG...
... Control is a device ... a filter between the ... tubing that captures nuclear ... and efficiency of phaco ...
Medicine Products: